Dracen Pharmaceuticals is a private pharmaceutical company that specializes in leveraging immuno-metabolism to develop innovative treatments for various types of cancer. Their goal is to directly shrink tumors and remodel the tumor microenvironment to make it more receptive to immuno-oncology approaches, leading to greater disease control, increased anti-tumor responses, and extended patient survival in areas of unmet need. Dracen's lead candidate, sirpiglenastat (DRP-104), is a unique glutamine inhibitor that irreversibly inhibits all known enzymes involved in glutamine metabolism.

This approach has shown single-agent anti-tumor activity across a wide spectrum of pre-clinical models, as well as the ability to remodel the tumor microenvironment and stimulate anti-tumor immune responses. Additionally, DRP-104 has demonstrated promising curative synergies with checkpoint inhibitors, offering substantial survival improvement even in models resistant to anti-PD-1 treatment. With a team of experienced leaders and a strong scientific foundation, Dracen Pharmaceuticals is dedicated to revolutionizing cancer treatment and improving patient outcomes